Skip to main content
Premium Trial:

Request an Annual Quote

Resolve Biosciences Raises $71M in Series B Financing

NEW YORK – Resolve Biosciences said on Monday that it has raised $71 million in Series B financing.

Patient Square Capital led the round, joined by EDBI, PS Capital, Alafi Capital, NRW.Bank, and other existing investors.

In a statement, Resolve said it plans to use the proceeds to scale operations and accelerate product development.

"With its talented team and proprietary Molecular Cartography technology, Resolve is leading the new era of single-cell spatial analysis and opening the door to a wave of scientific findings that will redefine our understanding of disease and lead to new therapies and improved patient outcomes," Patient Square Capital Partner Laura Furmanski said in a statement. She joined the firm's board of directors in conjunction with the investment.

Resolve, based in Monheim am Rhein, Germany, is commercializing a fluorescence in situ hybridization-based spatial transcriptomics method initially developed at Qiagen. The firm has now raised more than $100 million, including a $24 million Series A financing round in late 2020.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.